Isolation centers outside Lagos and Abuja is nothing to write home about. That's why they are running

They know they're OK but some people said they are not.
And the conditions of the centres are scary terrible

Nigeria sef confuse

too much mosquito

Quality20:
Well we got no covid in Igbo land

Imo state has 2

You don't know what good the government is doing for you to stay at home until you are being caught up with covid19 and be quarantined.

Because there is no light, and the one that was have was talking to those that have to avoid harvesting. Thanks

Ok

NaijaRoyalty:


Imo state has 2

. Oga is one(1) in imo. One is fully recovered remaining only one now as of this time of filing this report.

Seriously, the state of most isolation centres sef can make covid 19 patients lose hope of recovering

Why won't they run when they have lost hope in life, depressed, frustrated , and when Dem wan serve una food Dem go throw am like say na bingo u na be , isolation center is just like a cage in dis country sad but true

they knew that they don't have covid 19

Because they want to go and die at home. Period.

Hunger and mosquitoes

I think most of them are asymptomatic. They don't develop symptoms and they're being held at isolation center

Many of you don't even know most of these convid patients actually don't have the virus.. Many of them are having malaria , but these useless test kits will read positive for Corona virus

kponkedenge:
Isolation centers outside Lagos and Abuja is nothing to write home about. That's why they are running

Do you mean the weather is cold?

Christmasdon:
. Oga is one(1) in imo. One is fully recovered remaining only one now as of this time of filing this report.

Good to know then because I have people there

https://www.youtube.com/watch?v=SqYpCDo9HK0

Nigerian-Uk Woman Complains Of Being Traumatized For 43 Days In Isolation Center


A Nigerian woman who just returned from the United Kingdom on the 22nd of March, 2020, for her mother's burial was allegedly
isolated for 43days for contracting coronavirus.

mployer:
Some know deep down they don't have the virus.

If you are used to malaria symptoms and hoping a hospital will give you antimalarial injections, then suddenly they said it is covid19. Won't you japa?

It's the best option. Untreated malaria will kill, and the person will be recorded among covid19 deads.

That is why NCDC removed hydroxylchloroquine as a treatments drug, so that malaria fatality will recorded as covid19 fatality. Evil people.

Hydroxylchloroquine is not a Covid-19 cure. Stop spreading false information.

mployer:
Some know deep down they don't have the virus.

If you are used to malaria symptoms and hoping a hospital will give you antimalarial injections, then suddenly they said it is covid19. Won't you japa?

It's the best option. Untreated malaria will kill, and the person will be recorded among covid19 deads.

That is why NCDC removed hydroxylchloroquine as a treatments drug, so that malaria fatality will recorded as covid19 fatality. Evil people.

. U made a valid points here. U can't separate covid19 and malaria/typhoid symptoms.

eager to see their love ones again

KingAzubuike:
Many of you don't even know most of these convid patients actually don't have the virus.. Many of them are having malaria , but these useless test kits will read positive for Corona virus

I notice it when the drip used by the man was dump like the other site but on getting to the stage of the site I notice it was the federal government that owns the bus.

ddippset:
I think it's mostly bad conditions and stigma.

Nigerians can stigmatize people ehn.

By the time such people recover and return home don't be surprised that your neighbours would treat you like outcasts despite your recovery.

They will be looking at you somehow when you are passing and even tell their children not to play with yours.

Even after 2 years!

true.

Mosquitoes hunger fear

No.its hunger and lack of comfort.. I've seen the centres online and there's nothing Isolating about them.. the hunger complains everywhere are nothing to write about.are u aware that a high income man came out protesting that his abroad artivee daughter was been starved at the isolation centre? Gov is just imprisoning those peeps and starving them

Tissaia:
Fear of the unknown

Very clean 08 Camry bearly used @magodo 1.7million last. Hit my signature for this nice deal

sholarr12:
It's been reported several times that some Covid-19 patients ran away from isolation centres and I really find this surprising.

Why do I find it surprising? I do because a patient who runs away risks lack of proper medical care.

Once again, why would a Covid-19 patient run away?

some do not have symptoms but tested positive. they feel there are not sick.

Some patients are demonstrating right now in Gombe, because of poor treatment and negligence

mployer:
Some know deep down they don't have the virus.

If you are used to malaria symptoms and hoping a hospital will give you antimalarial injections, then suddenly they said it is covid19. Won't you japa?

It's the best option. Untreated malaria will kill, and the person will be recorded among covid19 deads.

That is why NCDC removed hydroxylchloroquine as a treatments drug, so that malaria fatality will recorded as covid19 fatality. Evil people.

Some of you enjoy making unfounded statements and I wonder why.

The article below is from Medscape.

https://www.medscape.com/viewarticle/928798?src=wnl_tp10n_200508_mscpedit&uac=194912BJ&impID=2373560&faf=1

No Hydroxychloroquine Benefit in Small, Randomized COVID-19 Trial

Marcia Frellick

April 16, 2020


Hydroxychloroquine (HCQ) does not help clear the SARS-CoV-2 virus or relieve symptoms for COVID-19 patients more than standard care alone and has more side effects, a randomized controlled trial of 150 hospitalized adults in China suggests.

However, two experts caution that because of confounding, the trial is unable to answer convincingly the question of whether HCQ can benefit COVID-19 patients.

Wei Tang, with the Departments of Pulmonology and Critical Care Medicine at Ruijin Hospital, in Shanghai, China, and colleagues enrolled patients with COVID-19 from 16 treatment centers in China in February. They posted their findings on the medRxiv preprint server, but their paper has not been peer reviewed. A coauthor told Medscape Medical News the work has been submitted to a journal.

The overall 28-day negative conversion rate of SARS-CoV-2, which was the primary endpoint, was similar in the two 75-patient treatment groups. The Kaplan-Meier estimate for negative conversion rate was 85.4% in the HCQ plus standard of care (SOC) arm, vs 81.3% in the SOC-only group (P = .341). Negative conversion rates for the two groups were similar at days 4, 7, 10, 14, and 21.

Adverse events were reported in 8.8% of patients in the control group compared with 30% in the HCQ group. Diarrhea was the most common side effect, occurring in 10% of patients in the HCQ group vs none in the control group. Two patients in the HCQ arm had serious adverse events; one experienced disease progression, and the other experienced upper respiratory tract infection.

Patients in the HCQ group received a high loading dose of 1200 mg daily for 3 days followed by a maintenance dose of 800 mg daily for the remaining days. Total duration was 2 weeks for patients with mild or moderate disease and 3 weeks for those with severe disease.

No Difference in Relief of Symptoms

The two arms were similar in alleviation of symptoms by day 28: 59.9% with HCQ plus SOC vs 66.6% with SOC alone.

However, the researchers said that in a post hoc analysis, they found a significant reduction of symptoms after adjusting for the confounding effects of antiviral agents (hazard ratio, 8.83; 95% confidence interval, 1.09 – 71.3).

In addition, Tang and colleagues report a significantly greater reduction of C-reactive protein (CRP), a biomarker for inflammation, from baseline to day 28 in the HCQ group in comparison with the control group (6.986 vs 2.723 mg/L).

The authors suggest the alleviation of symptoms may come from HCQ's anti-inflammatory effects.

The mean age of the patients was 46 years, and 55% were male. Almost all patients had mild or moderate disease; two had severe disease.

Experts Say Study Arms May Not Have Been Comparable

J. Michelle Kahlenberg, MD, PhD, research professor of rheumatology at the University of Michigan in Ann Arbor, told Medscape Medical News that it's important to note that in the post hoc analysis, 89% of the patients in this trial were receiving other therapy in addition to HCQ.

"When [the researchers] say they saw improvement in symptoms when they removed the confounders, what they actually did was remove the patients from the analysis that got antivirals, and that left 14 patients in each arm," Kahlenberg said.

Moreover, Kahlenberg noted, 20% of patients who received HCQ had mild symptoms, whereas only 9% of those in the SOC group did.

"We don't know how those patients played out in the post hoc analysis — whether it was the patients who were really mild that didn't get the antivirals that were left in the hydroxychloroquine group and that's why they had a slightly faster resolution of symptoms," she said.

She said that in this study, the researchers calculated CRP in milligrams per liter, whereas in the United States, it is measured in milligrams per deciliter. The conversion highlights the fact that the reduction in CRP was not terribly noteworthy, she said.

"The patients with COVID who tend to tank and have cytokine storms ― their CRP is much higher," she said. "So the small improvement in CRP wasn't that exciting.

"I don't think this gets us anywhere closer to an answer. It's another muddy study," she said.

Similarly, Christopher V. Plowe, MD, MPH, director of the Global Health Institute at Duke University in Durham, North Carolina, told Medscape Medical News he sees no convincing answers in this study.

Plowe, professor of medicine, molecular genetics, microbiology, and global health at Duke, also noted differences between the two groups at enrollment.

For example, the HCQ group had more than three times the number of patients with shortness of breath (22.1% vs 5.9%); more with sputum production (16.2 vs 5.9%); and more with cough (51.5% vs 38.2%). In addition, the average age was 4 years higher in the HCQ group.

"It makes me wonder whether the randomization was truly random," Plowe said.

Plowe also questioned the authors' statement that they didn't see cardiac arrhythmia events, such as prolonged QT intervals. "I can't see any evidence that they did an EKG on anybody," he said.

"This study leaves the door open to the possibility that hydroxychloroquine may have a clinical benefit. If there is a benefit, it seems to be related to the drug's anti-inflammatory properties. If that's the case, I'm not sure this particular drug, as opposed to others, would be the way to go," Plowe said.

Mixed Results in Other Studies

"Our negative results on the anti-viral efficacy of HCQ obtained in this trial are on the contrary to the encouraging in-vitro results and to the recently reported promising results from a non-randomized trial with 36 COVID-19 patients," the authors write.

However, the 36-patient trial to which they refer has since been called into question, as previously reported by Retraction Watch.

Despite lack of clear evidence of benefit, HCQ is recommended off label for the treatment of COVID-19 by the Chinese National guideline, and the US Food and Drug Administration has issued an emergency-use authorization for the treatment of adult patients with COVID-19.

By contrast, the Infectious Diseases Society of America recently concluded that because of insufficient data, they could not recommend any particular treatment for patients with COVID-19.

The work was supported by the Emergent Projects of National Science and Technology; the National Natural Science Foundation of China; the National Key Research and Development Program of China; the Shanghai Municipal Key Clinical Specialty; the National Innovative Research Team of High-Level Local Universities in Shanghai; the Shanghai Key Discipline for Respiratory Diseases; the National Major Scientific and Technological Special Project for Significant New Drugs Development; and Key Projects in the National Science and Technology Pillar Program. The authors, Kahlenberg, and Plowe have disclosed no relevant financial relationships.

Follow Medscape on Facebook, Twitter, Instagram, and YouTube. Have a tip for us? Contact us.